INVICTUS ANNOUNCES AB LABORATORIES INC. RECEIVES AMENDED LICENSE

World News: . []

Vancouver, B.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- is pleased to announce that AB Laboratories Inc. (“”) a company which is a 50% owned subsidiary of Invictus has received their amended license from Health Canada to include the new 40,000 sq. ft. custom built cultivation facility located near Hamilton, Ontario.

 

As previously announced on June 26, 2019, AB Labs’ facility contains ten identical cultivation rooms capable of producing over 65 crops annually on a tightly controlled weekly production schedule.  Five rooms have been propagated since receiving the amended license on August 30, 2019.  The initial harvest is scheduled for November 1, 2019.  The remaining rooms are expected to be propagated at a rate of one room per week over the next five weeks to ensure a reliable continuous production of cannabis for the recreational and medical markets.

 

Mr. Marc Ripa, Chief Operating Officer of Invictus and Chief Executive Officer of AB Labs and the other 50% owner of AB Labs stated, “AB Labs submitted the evidence package on June 4, 2019 and received the amended license from Health Canada in less than ninety days.   I am extremely pleased with the efficiency of Health Canada in processing AB Labs’ documentation.  The employees have been working extremely hard since receipt of the license to get the five rooms into production and are continuing to press on with the additional five rooms.”

 

Mr. Trevor Dixon, President and CEO of the Company said, “The completion of these ten rooms will double the Company’s volume of finished product going to market this year”.

 

For more information, please visit www.invictus-md.com.

 

Trevor Dixon

Chief Executive Officer

 

Investor Relations 1-844-800-6086

E-Mail: connect@invictus-md.com

 

 

Invictus is a global cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the Company’s medical clients and retail customers. The Company’s integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and sales to provinces.

 

To meet growing demand, Invictus is expanding its cultivation footprint with two cannabis production facilities licensed under the Cannabis Act, which replaced the Access to Cannabis for Medical Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary Acreage Pharms Ltd.’s (“”) Phase I and Phase II facilities are in full production.  Acreage is awaiting the amendment to their license from Health Canada to include the Phase III facility. AB Laboratories Inc., a company which is a 50% owned subsidiary of Invictus has completed it Phase II expansion and received its amended license from Health Canada. Another of Invictus’ wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise), continues to connect medical clients to physicians for medical cannabis and to Invictus’ fully licensed cannabis producers under the Cannabis Act.  Future Harvest Development Ltd., a company which is a 82.5% owned subsidiary of Invictus, continues to produce high-quality fertilizer and nutrients. Invictus is targeting up to 50 percent of production to medical cannabis. Invictus drives sustainable long-term shareholder value by continuing to develop Invictus’ Canadian production of medical and recreational cannabis products. For more information visit .

 

Kathy Love
Invictus
kathy@invictus-md.com

More news and information about Invictus

Published By:

Globe Newswire: 14:00 GMT Wednesday 11th September 2019

Published: .

Search for other references to "invictus" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us